Coronary heart disease secondary prevention weight management
|
Coronary heart disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coronary heart disease secondary prevention weight management On the Web |
|
American Roentgen Ray Society Images of Coronary heart disease secondary prevention weight management |
|
FDA on Coronary heart disease secondary prevention weight management |
|
CDC on Coronary heart disease secondary prevention weight management |
|
Coronary heart disease secondary prevention weight management in the news |
|
Blogs on Coronary heart disease secondary prevention weight management |
|
Risk calculators and risk factors for Coronary heart disease secondary prevention weight management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Weight Management
- If waist circumference is >35 inches in women and >40 inches in men, initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated.
- The initial goal of weight loss therapy should be to reduce body weight by approximately 5-10 percent from baseline or to achieve
- Body mass index: 18.5 to 24.9 kg/m2
- Waist circumference: men <40 inches, women <35 inches
AHA / ACC 2011 Guidelines - Coronary Heart Disease - Secondary Prevention with Weight Management (DO NOT EDIT) [1]
| Class I |
| "1. Body mass index and/or waist circumference should be assessed at every visit, and the clinician should consistently encourage weight maintenance/reduction through an appropriate balance of lifestyle physical activity, structured exercise, caloric intake, and formal behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 kg/m2. (Level of Evidence: B)" |
| "2. If waist circumference (measured horizontally at the iliac crest) is ≥35 inches (≥89 cm) in women and ≥40 inches (≥102 cm) in men, therapeutic lifestyle interventions should be intensified and focused on weight management (Level of Evidence: B)" |
| "3.The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from baseline. With success, further weight loss can be attempted if indicated. (Level of Evidence: C)" |
References
- ↑ Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA; et al. (2011). "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation". Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934.